Last 38 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Krystal Biotech, Inc.'s quarterly P/E stands at 35.3x, down 6.1% year-over-year.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 50.89 | 35.29 | 36.26 | 16.59 | 26.64 | 37.56 | 25.77 | 50.01 | 86.62 | 1482.75 | 103.38 | 10.39 | — |
| — | -6.1% | +40.7% | -66.8% | -69.2% | -97.5% | -75.1% | +381.1% | — | — | — | — | — | |
| P/S Ratio | 26.37 | 16.93 | 17.24 | 13.46 | 10.64 | 15.27 | 12.84 | 16.23 | 19.36 | 28.79 | 21.21 | 97.93 | — |
| — | +10.9% | +34.2% | -17.1% | -45.0% | -47.0% | -39.5% | -83.4% | — | — | — | — | — | |
| P/B Ratio | 8.55 | 6.17 | 6.05 | 4.63 | 3.93 | 5.47 | 4.95 | 6.14 | 6.49 | 6.52 | 4.59 | 4.43 | 4.79 |
| — | +12.9% | +22.4% | -24.7% | -39.4% | -16.1% | +7.7% | +38.6% | +35.4% | +55.1% | +18.4% | +34.3% | +59.7% | |
| P/FCF | 54.31 | 26.90 | 24.49 | 34.69 | 20.11 | 54.37 | 22.49 | 23.54 | — | 89.07 | — | — | — |
| — | -50.5% | +8.9% | +47.4% | — | -39.0% | — | — | — | — | — | — | — | |
| EV / EBITDA | 58.23 | 33.30 | 37.32 | 28.40 | 22.92 | 33.63 | 25.29 | 52.96 | 120.54 | — | 173.57 | — | — |
| — | -1.0% | +47.5% | -46.4% | -81.0% | — | -85.4% | — | — | — | — | — | — | |
| EV / EBIT | 60.60 | 34.37 | 45.56 | 25.45 | 23.82 | 35.15 | 26.24 | 36.33 | 60.58 | 208.93 | 75.65 | — | — |
| — | -2.2% | +73.6% | -29.9% | -60.7% | -83.2% | -65.3% | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Krystal Biotech, Inc.'s operating margin was 46.1% in Q1 2026, up 4.7 pp QoQ and up 5.1 pp YoY. The trailing four-quarter average of 42.7% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 92.6% | 94.6% | 89.8% | 94.2% | 92.5% | 94.3% | 94.6% | 92.0% | 91.5% | 94.7% | 89.6% | 97.4% | — |
| — | +0.3% | -5.0% | +2.4% | +1.2% | -0.4% | +5.5% | -5.5% | — | — | — | — | — | |
| Operating Margin | 41.5% | 46.1% | 41.5% | 42.3% | 40.9% | 41.0% | 45.4% | 26.8% | 12.2% | -14.8% | 7.4% | -303.8% | — |
| — | +12.5% | -8.6% | +58.1% | +235.8% | +377.7% | +509.7% | +108.8% | — | — | — | — | — | |
| Net Margin | 52.6% | 48.1% | 48.0% | 81.2% | 39.9% | 40.5% | 49.9% | 32.4% | 22.2% | 2.1% | 20.6% | 943.7% | — |
| — | +18.6% | -3.8% | +150.3% | +80.2% | +1867.3% | +141.9% | -96.6% | — | — | — | — | — |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 18.9% | 4.5% | 4.4% | 7.3% | 3.8% | 3.7% | 5.0% | 3.2% | 1.9% | 0.1% | 1.1% | 11.5% | -5.8% |
| — | +21.1% | -12.2% | +131.2% | +99.2% | +3033.7% | +338.2% | -72.5% | +132.7% | +101.3% | +118.8% | +311.2% | -14.5% | |
| ROA | 17.1% | 4.1% | 4.0% | 6.7% | 3.5% | 3.4% | 4.5% | 2.9% | 1.8% | 0.1% | 1.1% | 11.0% | -5.5% |
| — | +22.1% | -10.5% | +133.3% | +97.1% | +2908.8% | +313.0% | -73.9% | +132.2% | +101.3% | +119.1% | +316.1% | -18.4% | |
| ROIC | 18.0% | 5.3% | 4.5% | 4.3% | 4.3% | 4.2% | 5.5% | 3.3% | 1.4% | -1.1% | 0.6% | -5.0% | -7.7% |
| — | +27.2% | -18.5% | +29.6% | +215.1% | +466.5% | +857.9% | +165.7% | +117.6% | +88.6% | +108.1% | +24.1% | -13.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Krystal Biotech, Inc.'s Debt/EBITDA ratio is 0.0x, down from 0.2x last quarter — comfortably within a safe range.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | -85.6% | -0.2% | -0.9% | +1.5% | -0.7% | -26.2% | -23.3% | -29.9% | -44.8% | -39.2% | -34.8% | -19.9% | |
| Debt / EBITDA | 0.06 | 0.03 | 0.20 | 0.22 | 0.24 | 0.26 | 0.17 | 0.31 | 0.73 | — | 1.74 | — | — |
| — | -87.3% | +19.5% | -29.1% | -67.4% | — | -90.3% | — | — | — | — | — | — | |
| Current Ratio | 9.95 | 9.46 | 9.95 | 10.14 | 9.68 | 9.65 | 7.28 | 7.97 | 9.50 | 12.66 | 17.76 | 21.10 | 20.25 |
| — | -1.9% | +36.8% | +27.3% | +1.9% | -23.8% | -59.0% | -62.3% | -53.1% | +24.9% | +33.5% | +48.8% | +62.6% | |
| Quick Ratio | 9.56 | 9.06 | 9.56 | 9.73 | 9.33 | 9.27 | 7.02 | 7.76 | 9.33 | 12.42 | 17.55 | 20.91 | 20.25 |
| — | -2.2% | +36.3% | +25.4% | -0.1% | -25.4% | -60.0% | -62.9% | -53.9% | +22.6% | +31.9% | +47.5% | +62.6% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 38 years · Updated daily
Deep dive into KRYS consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying KRYS stock.
Krystal Biotech, Inc.'s current P/E is 50.9x. The average P/E over the last 4 quarters is 28.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Krystal Biotech, Inc.'s current operating margin is 41.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Krystal Biotech, Inc.'s business trajectory between earnings reports.